The in vitro activities of LY146032 and seven comparative antimicrobial agents against 14 species of staphylococci, streptococci, and enterococci were studied. MICs of LY146032 were .0.5 jig/ml for all staphylococci, including oxacillin-resistant strains; .0.25 jug/ml for all streptococci (except viridans group streptococci); and .4 jug/ml for all viridans group streptococci and enterococci. MICs were minimally affected by variations in inoculum size, and LY146032 was bactericidal against all species tested.
used.
MICs were determined by a standardized microdilution method (2) in 0.1-ml volumes of cation-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.). For supplementation, 45 mg of calcium per liter and 25 mg of magnesium per liter were added to Mueller-Hinton broth; physiologic concentrations were confirmed by testing the activity of gentamicin against Pseudomonas aeruginosa ATCC 27853 (2) . For Streptococcus pyogenes and Streptococcus pneumoniae, the medium was supplemented with 1% heat-inactivated horse serum. Microdilution plates were inoculated with disposable inoculators (Dynatech) which * Corresponding author. deliver 10 [lI per well so that the inoculum was 5 x 105 to 1 x 106 CFU/ml. To distinguish oxacillin-susceptible from oxacillin-resistant staphylococci, a modification (4) of the microdilution test was used; criteria were that MICs .2 jig/ml were considered susceptible and MICs .16 ,ug/ml were considered resistant for Staphylococcus aureus and Staphylococcus haemolyticus, and MICs .0.25 jxg/ml were considered susceptible and .16 jig/ml were considered resistant for Staphylococcus epidermidis.
The MICs of the study drugs for the 316 strains are shown in Table 1 . MICs of LY146032 were .0.5 jug/ml for all staphylococci, including oxacillin-resistant strains; .0.25 ,ug/ml for all streptococci (except viridans group streptococci); and .4 ,ug/ml for all viridans group streptococci and enterococci. There was no correlation of relative susceptibility or resistance between LY146032 and other drugs against any species. For 85 of the study strains (5 strains each of the organisms listed in Table 1 ), the effects of inoculum size variation on MICs were determined by simultaneously testing the standard inoculum and inocula 10-fold higher and 10-fold lower. Variations of 100-fold had little effect (.2 dilution steps) with any drug, with the following exceptions: ampicillin against penicillinase-producing and oxacillin-resistant staphylococci; oxacillin, cephalothin, and imipenem against oxacillin-resistant staphylococci; gentamicin against viridans group streptococci; and rifampin against occasional enterococci.
To determine MBCs for the same 85 strains, the wells from MIC plates containing an initial inoculum of 5 x 105 to 1 x 106 CFU/ml were subcultured (10 pA) to 0.1-ml volumes of antimicrobial-free broth to detect a .99.9% reduction in CFU/ml (3). With LY146032, MBCs were .2 dilution steps higher than respective MICs for all species. With other drugs, MBCs were usually <2 dilution steps higher than respective MICs for susceptible strains of staphylococci and streptococci, but enterococci were often resistant or had higher MBC/MIC ratios. The results of this and another (1) study indicate that LY146032 has a favorable profile of antibacterial activity against staphylococci, streptococci, and enterococci. 
